Search

Survivin is an inhibitor of apoptosis protein and has a crucial role in the development of cancer. The survivin -31G>C (rs9904341) promoter polymorphism influences survivin expression and has been implicated in cancer risk. However, conflicting results have been published from studies on the association between survivin -31G>C polymorphism and the risk of cancer. To clarify the role of this polymorphism in cancer, we performed a meta-analysis of all available and relevant published studies, involving a total of 3485 cancer patients and 3964 control subjects. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations. The overall results indicated that the variant genotypes were associated with a significantly increased cancer risk (CC vs GG: OR=1.58, 95% CI=1.20-2.10; CC/GC vs GG: OR=1.23, 95% CI=1.00-1.51; CC vs GG/GC: OR=1.51, 95% CI=1.23-1.85). In the stratified analyses, significantly increased risk was associated with the Asian populations (CC vs GG: OR=1.67, 95% CI=1.16-2.40; CC vs GG/GC: OR=1.50, 95% CI=1.17-1.91). We also performed the analyses by cancer type, and no statistical association was observed. The results suggest that the survivin -31G>C promoter polymorphism might be associated with an increased risk of cancer, especially in the Asian populations.

Objective: Recently, a common insertion/deletion (-94insertion/deletion ATTG, rs28362491) polymorphism in the NFkappaB1 promoter region has been extensively investigated for association with cancer risk but the results have been inconsistent. In order to clarify the effect of the promoter polymorphism we performed an update meta-analysis of published case-control studies to better compare the results between studies., Methods: Relevant studies were identified via a thorough literature search on Medline and Embase database (up to August 10, 2011). The odds ratio (OR) and 95% confidence interval (95%CI) were used to investigate the strength of the association., Results: A total of 5,196 cases and 6,614 controls in 19 case-control studies from 16 publications were included in this meta-analysis. Overall, the variant genotypes were associated with a moderately decreased risk of all cancer types (OR =0.74, 95%CI =0.57-0.97 for DD versus II; OR =0.79, 95%CI =0.66-0.95 for DD versus II/ID). In the stratified analyses, significantly decreased risk was found among Asians (OR =0.52, 95%CI =0.42-0.65 for DD versus II; OR =0.74, 95%CI =0.66-0.83 for ID versus II; OR =0.64, 95%CI =0.53-0.78 for DD versus II/ID; OR =0.68, 95%CI =0.61-0.75 for DD/ID versus II). The validity of this association was further strengthened by the sensitivity analysis. No publication bias was observed in this study., Conclusions: Our results suggested that the -94deletion ATTG promoter polymorphism in NFkappaB1 gene might be associated with a decreased cancer risk, especially for Asian population.

The upregulation or mutation of C-MYC has been observed in gastric, colon, breast, and lung tumors and in Burkitt's lymphoma. However, little is known about the role C-MYC plays in gastric adenocarcinoma. In the present study, we intended to investigate the influence of C-MYC on the growth, proliferation, apoptosis, invasion, and cell cycle of the gastric cancer cell line SGC7901 and the gastric cell line HFE145. C-MYC cDNA was subcloned into a constitutive vector PCDNA3.1 followed by transfection in normal gastric cell line HFE145 by using liposome. Then stable transfectants were selected and appraised. Specific inhibition of C-MYC was achieved using a vector-based siRNA system which was transfected in gastric cancer cell line SGC7901. The apoptosis and cell cycles of these clones were analyzed by using flow cytometric assay. The growth and proliferation were analyzed by cell growth curves and colony-forming assay, respectively. The invasion of these clones was analyzed by using cell migration assay. The C-MYC stable expression clones (HFE-Myc) and C-MYC RNAi cells (SGC-MR) were detected and compared with their control groups, respectively. HFE-Myc grew faster than HFE145 and HFE-PC (HFE145 transfected with PCDNA3.1 vector). SGC-MR1, 2 grew slower than SGC7901 and SGC-MS1, 2 (SGC7901 transfected with scrambled control duplexes). The cell counts of HFE-Myc in the third, fourth, fifth, sixth, and seventh days were significantly more than those of control groups (P < 0.05). Those of SGC-MR1, 2 in the fourth, fifth, sixth, and seventh days were significantly fewer than those of control groups (P < 0.05). Cell cycle analysis showed that proportions of HFE-Myc and SGC-MR cells in G0-G1 and G2-M were different significantly with their control groups, respectively (P < 0.05). The apoptosis rate of HFE-Myc was significantly higher than those of control groups (P < 0.05). Results of colony-forming assay showed that the colony formation rate of HFE-Myc was higher than those of control groups; otherwise, the rate of SGC-MR was lower than those of their control groups (P < 0.05). The results of cell migration assay showed that there were no significant differences between experimental groups and control groups (P > 0.05). In conclusion, C-MYC can promote the growth and proliferation of normal gastric cells, and knockdown of C-MYC can restrain the growth and proliferation of gastric cancer cells. It can induce cell apoptosis and help tumor cell maintain malignant phenotype. But it can have not a detectable influence on the ability of invasion of gastric cancer cells.

Hexadepsipeptide 2, the precursor of Hirsutellide A (1), was synthesized in an overall yield of 45% from N-Boc-Me-Gly via three coupling reactions using dicyclohexylcarbodiimide (DCC), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyl- uronium hexafluorophosphate (HATU) and bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl), respectively.

The catalytic reactivity and selectivity of the first example of a nanostructured solid acid resin (1) are described. This new type of solid acid catalyst is formed by the self-assembly and copolymerization of two acidic lyotropic liquid crystals (LLCs), affording a columnar hexagonal polymer network with monodisperse nanochannels lined with sulfonic acid groups. The performance of this material as a heterogeneous catalyst was compared against that of two commercially available, amorphous sulfonic acid resins: Amberlyst-15 and Nafion NR50. Using the acid-catalyzed esterification of benzyl alcohol with 1-hexanoic acid in dry toluene as a test reaction, it was found that resin 1 displayed only slightly lower overall reactivity as compared to Amberlyst-15 and Nafion NR50 but more than an order of magnitude higher selectivity for the desired ester product over dibenzyl ether side-product. Control experiments revealed that the higher product selectivity is not due to differences in relative acidity between the nanostructured acid resin and the two amorphous resins. Instead, it appears that a large component of the enhanced selectivity is due to the regular nanostructure present in the LLC resin, which affords a much more uniform local acid microenvironment for reactions to occur. Resin 1 can also be recycled with almost complete recovery of catalytic activity and selectivity, and with essentially no leaching of reactive groups into the solution phase.

Objective: To study the diagnosis and treatment of thymoma and to assess its prognostic factors., Methods: The clinical data of 116 patients with thymoma were collected. A retrospective analysis was performed, by comparing the survival rate calculated by the Kaplan-Meier method with the rate of recurrence or metastasis., Results: The standard posteroanterior and lateral chest radiographs were reliable means of detection of most thymomas. Myasthenia gravis was the most commonly paraneoplastic disease (25.0%, 29/116). The extensive radical resection was beneficial for reducing the rate of recurrence of stage I or stage II thymomas (chi(2) = 4.941, P = 0.0219). The survival time could be prolonged by postoperative radiotherapy and chemotherapy. There was a strong correlation between the clinical stage and the histological classification (according to MH classification), through which the invasive behavior of thymoma could be predicted (chi(2) = 19.76, P = 0.007, RR = 1.47). The 3- 5- and 10-year survival rates were 81.2%, 67.9%, and 40.5%, respectively. Statistical analysis showed a significant negative correlation between the stage and the survival rate (chi(2) = 29.73, P = 0.0000, RR = 0.15)., Conclusion: The prognosis of thymoma depends mainly on the histological classification, clinical stage and multimodality treatment rather than on the paraneoplastic diseases.

Objectives: To study the diagnosis and treatment of thymoma and to assess prognosis factors., Methods: The clinical data on 116 patients with thymoma were collected. A retrospective analysis was performed by comparison of their survival rates computed by the actuarial method and rate of recurrence and metastasis., Results: Chest radiograph was used chiefly for the preoperative diagnosis of thymoma; myasthenia gravis (MG) (25.0%, 29/116) was the most common paraneoplastic disease. An extensive and radical resection was carried out to reduce the recurrence rate of thymoma with stage I and stage II (chi(2) = 4.941 P = 0.0219). The survival time was prolonged by postoperative radiotherapy and chemotherapy. A strong correlation was noted between the clinical stage and histologic subtype of M-H classification, by which the invasive behavior of thymoma was predicted (r = 0.385, P = 0.007). The 3-, 5-, and 10-year survival rates were 81.2%, 67.9% and 40.5%, respectively. Statistical analysis showed a significant negative correlation between stage and survival rate (r = -0.897, P = 0.0000)., Conclusion: The prognosis of thymoma depends mainly on the histologic subtype, clinical stage and multimodality treatment rather than paraneoplastic diseases.